ea0089c12 | Clinical – Chemo/SSA/Biologics | NANETS2022
Mariam Roy Arya
, Kaur Jasmine
, Attwood Kristopher
, Iyer Renuka
Background: With the advent of new therapeutic modalities, the overall survival of neuroendocrine tumor (NET) patients has increased. However, the impact of the symptoms, treatments on the quality of life (QoL) of the patients, accessibility to health care, and financial toxicity are underreported in the literature. We have established a prospective NET biobank to capture the burden of the disease on patientsÂ’ daily life and the impact on their QoLM...